H. Moses Murdock - Concepedia

Concepedia

Author

H. Moses Murdock

Dana-Farber Cancer Institute ORCID

Also Known As

H Moses Murdock, H Murdock, H. Moses Murdock, Heardley M. Murdock, Heardley Murdock, Heardley M. Murdock, Heardly Moses Murdock

46

Publications

1.1K

Citations

14

H-Index

38

Concepts

All Affiliations

Dana-Farber Cancer Institute University of Pennsylvania National Institute of Allergy and Infectious Diseases National Institutes of Health Brigham and Women's Hospital

HM

About

H. Moses Murdock is an author at Dana-Farber Cancer Institute specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	320
2	Arts	1	1	73
3	Education	1	1	73
4	Health Sciences	1	1	33
5	Natural Sciences	1	1	62

H. Moses Murdock

×

14

Publications

1.1K

Citations

14

H-Index

	Year	Citations
Trends in Racial/Ethnic Representation Among US Medical Students Elle Lett, H. Moses Murdock, Whitney Orji, JAMA Network Open	2019	331
DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity Qian Zhang, Christopher G. Dove, Jyh Liang Hor, The Journal of Experimental Medicine Inherited Combined ImmunodeficiencySkin Antiviral ImmunityMedicineViral PathogenesisImmunology	2014	167
Recurrent rhinovirus infections in a child with inherited MDA5 deficiency Ian T. Lamborn, Huie Jing, Yu Zhang, The Journal of Experimental Medicine	2017	144
Virtual Morning Report during COVID‐19: A novel model for case‐based teaching conferences H. Moses Murdock, John C. Penner, Stephenie Le, Medical Education Virtual Morning ReportTeachingHealth CommunicationCovid-19 PandemicOnline Teaching	2020	73
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML H. Moses Murdock, Haesook T. Kim, Nathan Denlinger, Blood	2022	69
Dual Proteolytic Pathways Govern Glycolysis and Immune Competence Wei Lü, Yu Zhang, David McDonald, Cell MedicineNatural SciencesImmunologyAutoimmunityImmune System	2014	62
Matched Related and Unrelated Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency Jennifer Cuellar‐Rodríguez, Alexandra F. Freeman, Jennifer Grossman, Biology of Blood and Marrow Transplantation	2015	50
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) R. Coleman Lindsley, Christopher J. Gibson, H. Moses Murdock, Blood	2019	45
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active Jacqueline S. Garcia, Haesook T. Kim, H. Moses Murdock, Blood Advances Ric TransplantHematological MalignancyTransplantationOncologyDose-escalated Venetoclax	2021	41
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML Jacqueline S. Garcia, Haesook T. Kim, H. Moses Murdock, Blood Advances Mixed-phenotype Acute LeukemiaTransplantation MedicineImmunologyPharmacotherapyImmunotherapy	2024	33

Page 1